Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma | Biolojic Design

Categories: News | Published On: December 14, 2023 | Written by Brandon Tilley |

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

More News

Biolojic Design Appoints Roger Waltzman as Chief Medical Officer
Read More
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Read More

BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com